These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 30182361)
21. Natural history of graves' orbitopathy after treatment. Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471 [TBL] [Abstract][Full Text] [Related]
22. Decreased Frequencies of Peripheral Blood CD4+CD25+CD127-Foxp3+ in Patients with Graves' Disease and Graves' Orbitopathy: Enhancing Effect of Insulin Growth Factor-1 on Treg Cells. Pawlowski P; Grubczak K; Kostecki J; Ilendo-Poskrobko E; Moniuszko M; Pawlowska M; Rejdak R; Reszec J; Mysliwiec J Horm Metab Res; 2017 Mar; 49(3):185-191. PubMed ID: 28222462 [TBL] [Abstract][Full Text] [Related]
23. Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients. Esteghamati A; Khalilzadeh O; Mobarra Z; Anvari M; Tahvildari M; Amiri HM; Rashidi A; Solgi G; Parivar K; Nikbin B; Amirzargar A Eur J Intern Med; 2009 Jul; 20(4):424-8. PubMed ID: 19524188 [TBL] [Abstract][Full Text] [Related]
24. Interaction of lymphocytes and thyrocytes in Graves' disease and nonautoimmune thyroid diseases in immunohistochemical and ultrastructural investigations. Ben-Skowronek I; Sierocinska-Sawa J; Szewczyk L; Korobowicz E Horm Res; 2009; 71(6):350-8. PubMed ID: 19506393 [TBL] [Abstract][Full Text] [Related]
25. [Novel treatment opportunities in Graves' orbitopathy]. Erdei A; Gazdag A; Bodor M; Berta E; Katkó M; Ujhelyi B; Steiber Z; Győry F; Urbancsek H; Barna S; Galuska L; Nagy VE Orv Hetil; 2014 Aug; 155(33):1295-300. PubMed ID: 25109914 [TBL] [Abstract][Full Text] [Related]
26. Euthyroid Graves' ophthalmopathy with negative autoantibodies. Cakir M J Natl Med Assoc; 2005 Nov; 97(11):1547-9. PubMed ID: 16334503 [TBL] [Abstract][Full Text] [Related]
27. [Role of Treg/Th17 cells and related cytokines in Graves' ophthalmopathy]. Lv M; Shen J; Li Z; Zhao D; Chen Z; Wan H; Hao B Nan Fang Yi Ke Da Xue Xue Bao; 2014 Dec; 34(12):1809-13. PubMed ID: 25537908 [TBL] [Abstract][Full Text] [Related]
29. Abnormal B lymphocyte function in thyroid glands from patients with Graves' disease. Ueki Y; Eguchi K; Otsubo T; Kawabe Y; Shimomura C; Tezuka H; Nakao H; Kawakami A; Migita K; Ishikawa J Clin Endocrinol Metab; 1989 Nov; 69(5):939-45. PubMed ID: 2793996 [TBL] [Abstract][Full Text] [Related]
30. Novel treatment modalities for Graves' orbitopathy. Bartalena L; Lai A; Sassi L; Lombardi V; Dalle Mule I; Gandolfo M; Liparulo L; Azzolini C; Piantanida E; Tanda ML Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():210-6. PubMed ID: 20467365 [TBL] [Abstract][Full Text] [Related]
31. Parameters predicting outcomes of strabismus surgery in the management of Graves' ophthalmopathy. Nassar MM; Dickinson AJ; Neoh C; Powell C; Buck D; Galal E; Clarke MP J AAPOS; 2009 Jun; 13(3):236-40. PubMed ID: 19395292 [TBL] [Abstract][Full Text] [Related]
32. Immunological Features of Paranasal Sinus Mucosa in Patients with Graves' Orbitopathy. Lu Y; Wu Y; Huang Y; Fang S; Li Y; Sun J; Zhou H Front Endocrinol (Lausanne); 2020; 11():621321. PubMed ID: 33643223 [TBL] [Abstract][Full Text] [Related]
33. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy. Woo YJ; Jang SY; Lim TH; Yoon JS Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504 [TBL] [Abstract][Full Text] [Related]
34. Immunopathogenesis of thyroid eye disease: emerging paradigms. Naik VM; Naik MN; Goldberg RA; Smith TJ; Douglas RS Surv Ophthalmol; 2010; 55(3):215-26. PubMed ID: 20385333 [TBL] [Abstract][Full Text] [Related]
35. Graves'-like orbitopathy in a patient with chronic autoimmune pancreatitis. Fonte R; Pirali B; Caramia V; Dionisio R; Lodigiani S; Sibilla L; Rotondi M; Chiovato L Thyroid; 2011 Dec; 21(12):1389-92. PubMed ID: 22066480 [TBL] [Abstract][Full Text] [Related]
36. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases. Molnár I; Bokk A Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110 [TBL] [Abstract][Full Text] [Related]
37. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy. Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519 [TBL] [Abstract][Full Text] [Related]
38. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study. Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054 [TBL] [Abstract][Full Text] [Related]
39. Thyroid eye disease or Graves' orbitopathy: What name to use, and why it matters. Wagner LH; Bradley EA; Tooley AA; Ren Y; Rachmasari KN; Stan MN Front Endocrinol (Lausanne); 2022; 13():1083886. PubMed ID: 36518254 [TBL] [Abstract][Full Text] [Related]
40. Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells. Karlsson FA; Tötterman TH Clin Exp Immunol; 1988 Nov; 74(2):258-63. PubMed ID: 2906281 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]